Zura Bio Limited (ZURA) Company Overview

Profile

Full Name:

Zura Bio Limited

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

March 21, 2023

Indexes:

Not included

Description:

Zura Bio Limited is a biotechnology company focused on developing innovative therapies for autoimmune diseases. They aim to improve patient outcomes by creating targeted treatments that address the underlying causes of these conditions, using advanced scientific research and technology.

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Mar 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 24, 24 HC Wainwright & Co.
Neutral
Dec 11, 24 Cantor Fitzgerald
Overweight
Nov 18, 24 HC Wainwright & Co.
Neutral
Nov 11, 24 HC Wainwright & Co.
Neutral
Nov 9, 24 Chardan Capital
Buy
Nov 4, 24 Leerink Partners
Outperform
Oct 21, 24 HC Wainwright & Co.
Neutral
Oct 18, 24 Cantor Fitzgerald
Overweight
Sep 19, 24 Piper Sandler
Overweight
Sep 5, 24 HC Wainwright & Co.
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
ZURA
businesswire.comNovember 25, 2024

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY. A live webcast and a replay of the presen.

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
ZURA
businesswire.comNovember 14, 2024

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody designed to neutralize both IL-17A.

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
ZURA
businesswire.comJune 14, 2024

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren's syndrome. These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presented at the Annual European Co.

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
ZURA
businesswire.comJune 3, 2024

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data from its tibulizumab (ZB-106) program exploring the clinical potential of the dual-pathway antibody in Sjogren's syndrome and rheumatoid arthritis (RA) at EULAR 2024, June 12-15 in Vienna. “We are excited to present translational data from our tibulizumab (ZB-106.

Zura Bio Announces Participation in June Investor Conferences
Zura Bio Announces Participation in June Investor Conferences
Zura Bio Announces Participation in June Investor Conferences
ZURA
businesswire.comMay 29, 2024

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June. Conference Details: Event: Jefferies Global Healthcare Conference Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in one-on-one meetin.

How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%
How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%
How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%
ZURA
Zacks Investment ResearchMay 15, 2024

The average price targets from Wall Street analysts suggest a potential upside of 248.8% for Zura Bio Limited (ZURA). Although the reliability of this metric is uncertain, the positive trend in earnings estimate revisions could lead to an increase in the stock's value.

Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should Know
Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should Know
Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should Know
ZURA
Zacks Investment ResearchMay 14, 2024

Zura Bio Limited (ZURA) could see an increase in its stock price due to increasing confidence in its earnings potential, as evidenced by its upgrade to a Zacks Rank #2 (Buy).

Why Shares of Zura Bio Climbed Tuesday
Why Shares of Zura Bio Climbed Tuesday
Why Shares of Zura Bio Climbed Tuesday
ZURA
The Motley FoolJune 20, 2023

Zura Bio's lead therapy is ZB-106. The company plans to start two phase 2 trials for the therapy.

ZURA Stock Alert: Zura Bio SPAC Merger Rally Ends
ZURA Stock Alert: Zura Bio SPAC Merger Rally Ends
ZURA Stock Alert: Zura Bio SPAC Merger Rally Ends
ZURA
InvestorPlaceMarch 23, 2023

Zura Bio (NASDAQ: ZURA ) stock is on the move Thursday following the clinical-stage biotechnology company's recent public debut. Zura Bio went public on Tuesday after completing its special purpose acquisition company (SPAC) merger with JATT Acquisition Corp. Afterward, the company's shares saw a massive spike in price during trading on Wednesday.

FAQ

  • What is the ticker symbol for Zura Bio Limited?
  • Does Zura Bio Limited pay dividends?
  • What sector is Zura Bio Limited in?
  • What industry is Zura Bio Limited in?
  • What country is Zura Bio Limited based in?
  • When did Zura Bio Limited go public?
  • Is Zura Bio Limited in the S&P 500?
  • Is Zura Bio Limited in the NASDAQ 100?
  • Is Zura Bio Limited in the Dow Jones?
  • When was Zura Bio Limited's last earnings report?
  • When does Zura Bio Limited report earnings?
  • Should I buy Zura Bio Limited stock now?

What is the ticker symbol for Zura Bio Limited?

The ticker symbol for Zura Bio Limited is NASDAQ:ZURA

Does Zura Bio Limited pay dividends?

No, Zura Bio Limited does not pay dividends

What sector is Zura Bio Limited in?

Zura Bio Limited is in the Healthcare sector

What industry is Zura Bio Limited in?

Zura Bio Limited is in the Biotechnology industry

What country is Zura Bio Limited based in?

Zura Bio Limited is headquartered in United States

When did Zura Bio Limited go public?

Zura Bio Limited's initial public offering (IPO) was on March 21, 2023

Is Zura Bio Limited in the S&P 500?

No, Zura Bio Limited is not included in the S&P 500 index

Is Zura Bio Limited in the NASDAQ 100?

No, Zura Bio Limited is not included in the NASDAQ 100 index

Is Zura Bio Limited in the Dow Jones?

No, Zura Bio Limited is not included in the Dow Jones index

When was Zura Bio Limited's last earnings report?

Zura Bio Limited's most recent earnings report was on Nov 7, 2024

When does Zura Bio Limited report earnings?

The next expected earnings date for Zura Bio Limited is Mar 28, 2025

Should I buy Zura Bio Limited stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions